To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Utilizing microphysiologi… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting

Journal article
Authors K. M. Fabre
Louise Delsing
R. Hicks
N. Colclough
D. C. Crowther
L. Ewart
Published in Advanced Drug Delivery Reviews
Volume 140
Pages 129-135
ISSN 0169-409X
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 129-135
Language en
Links dx.doi.org/10.1016/j.addr.2018.09.0...
Keywords Microphysiological systems, Organs-on-chips, Tissue chips, Stem cells, iPSC, Blood brain barrier, Pharmaceutical, Drug development, in-vitro model, drug discovery, efficient generation, endothelial-cells, cns, differentiation, inflammation, permeability, penetration, crispr/cas9, Pharmacology & Pharmacy
Subject categories Pharmaceutical Sciences

Abstract

Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics. Published by Elsevier B.V.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?